In the aging society, the issue of coronary chronic total occlusion (CTO) has become a challenge for invasive cardiologists. Despite the lack of clear indications in European and American guidelines, the rates of percutaneous coronary interventions (PCI) for CTO increased over the last years. Well-conducted randomized clinical trials (RCT) and large observational studies brought significant and substantial progress in many CTO blind spots. However, the results regarding the rationale behind revascularization and the long-term benefit of CTO are inconclusive. Knowing the uncertainties regarding PCI CTO, our work sought to sum up and provide a comprehensive review of the latest evidence on percutaneous recanalization of coronary artery chronic total occlusion.

Atrial fibrillation (AF) is the most common arrhythmia worldwide, and is associated with a significant risk of thromboembolic events. Left atrial appendage occlusion (LAAO) has emerged as a promising alternative for patients with contraindications or intolerance to anticoagulant therapy. This review summarises the current evidence, indications, and technical advancements in surgical and percutaneous LAAO. Preprocedural planning relies on various imaging techniques, each with unique advantages and limitations. The existing randomised clinical trials and meta-analyses demonstrate favourable results for both percutaneous and surgical LAAO. Postprocedural management emphasises personalised anticoagulation strategies and comprehensive imaging surveillance to ensure device stability and detect complications. Future focus should be put on antithrombotic regimens, investigating predictors of device-related complications, and simplifying procedural aspects to enhance patient outcomes. In summary, LAAO is presented as a valuable therapeutic option for preventing AF-related thromboembolic events, with ongoing research aimed at refining techniques and improving patient care.

Background/Objectives: Sudden cardiac death (SCD) remains a major global health concern and represents one of the most common causes of mortality due to cardiovascular diseases. The wearable cardioverter–defibrillator (WCD) is an innovative, non-invasive medical device designed to provide continuous heart monitoring and immediate defibrillation in patients at risk for SCD. The study aimed to assess the efficacy of WCD usage in patients awaiting decision on therapy with implantable cardioverter–defibrillators (ICDs). Methods: We explored the clinical applications, benefits, and limitations of WCD usage within the BIA-VEST registry in Poland over the years 2021–2023. The study included 10 patients with a mean age of 49.1 ± 12.02 years. Results: All patients demonstrated good tolerance and compliance with the LifeVest WCD, wearing it for an average of 93.1 days, about 22.8 h per day (95.7% of the time). No interventions from LifeVests were recorded, and there were no effective, ineffective, or inadequate discharges. After the first follow-up echocardiography, five patients still required ICDs. Due to improved LVEF and overall condition in six out of ten patients undergoing WCD bridge therapy, ICD implantation was finally waived. Conclusions: The WCD acts as a bridge to therapy, such as ICD implantation or cardiac surgery, and may be particularly beneficial for patients with transient or evolving conditions, such as structural heart diseases and life-threatening ventricular arrhythmias.

Background: The no-reflow phenomenon remains a frequent and clinically significant complication in patients with ST-segment elevation myocardial infarction (STEMI) despite advances in primary percutaneous coronary intervention (pPCI). Its determinants are multifactorial and not fully established. This study aimed to identify independent predictors of impaired reperfusion after pPCI. Methods: In this prospective study, 100 consecutive STEMI patients treated with successful pPCI in a high-volume tertiary center were analyzed. Impaired reperfusion was defined as ST-segment resolution < 50% or final TIMI flow < 3. Clinical characteristics, laboratory findings, including platelet reactivity, and detailed angiographic and procedural parameters were collected. Independent predictors were evaluated using multivariable logistic regression. Thirty-day and twelve-month mortality were assessed with Kaplan–Meier analysis. Results: Impaired reperfusion occurred in 39% of patients. Compared with the normal reperfusion group, patients with noreflow were older, had lower left ventricular ejection fraction, eGFR, longer ischemia times, and more often presented with anterior STEMI. Platelet reactivity did not differ between groups. Four variables independently predicted impaired reperfusion: longer pain-to-balloon time (OR 1.05 per 10 min, 95% CI 1.02–1.07; p < 0.001), anterior myocardial infarction (OR 5.05, 95% CI 1.14–22.38; p = 0.03), use of predilatation (OR 7.66, 95% CI 1.78–32.9; p = 0.006), and higher Killip–Kimball class (OR 7.69, 95% CI 1.88–31.38; p = 0.004). Impaired reperfusion was associated with significantly higher mortality at 30 days (1.6% vs. 10%; p < 0.001) and 12 months (3.2% vs. 25.6%; p < 0.001). Conclusions: In this prospective STEMI cohort, impaired reperfusion was frequent and strongly associated with adverse short- and long-term outcomes. Ischemia duration, infarct location, hemodynamic status, and procedural strategy were key determinants of noreflow, while platelet reactivity showed no significant association.